Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------
Symrise, one of the world's leading suppliers of fragrances, active
cosmetic ingredients and flavorings, has acquired a 20 percent stake
in the US biotechnology company Therapeutic Peptides Inc. (TPI), thus
securing exclusive distribution rights for highly advanced cosmetic
active ingredients.
In acquiring a stake in TPI, Symrise gains access to the
ultra-innovative group of active ingredients known as peptides, which
the company can immediately offer to its customers in the
international cosmetics industry. Peptides are used as anti-microbial
substances and in anti-aging skin care products, for example, and
stimulate hair growth. "It is only just recently that peptides have
been used in cosmetic products. We are delighted to be able to
integrate these modern and very effective ingredients in our
portfolio. With TPI, we have found a partner who is developing these
ingredients at a scientifically exalted level and can offer ample
expertise in this field," stated Dr. Klaus Stanzl, President Scent &
Care, Life Essentials. In connection with the Symrise shareholding in
TPI, Klaus Stanzl has also been elected to its Supervisory Board.
With the Symrise stake, the Louisiana-based US company Therapeutic
Peptides Inc. will have fresh resources available for maintaining its
intensive research work. "Symrise is for us the ideal partner. It
opens up worldwide distribution opportunities for our substances,"
declared Dr. Donald Owen, founder and managing director of TPI.
Symrise's stake in TPI represents a further, strategically wise
expansion of its portfolio of cosmetic ingredients. Exclusive
distribution of modern and highly efficient peptides, whose
effectiveness is scientifically proven, will enable the company to
react to the growing demand from its customers in this field.
About Symrise
Symrise is a global supplier of fragrances, flavorings and raw
materials and active ingredients for the perfume, cosmetics and food
industry.
Its sales of ¤1.27 billion in 2007 place the company among the top
four in the international flavors and fragrances market.
Headquartered in Holzminden, Germany, Symrise is represented in more
than 30 countries in Europe, Asia, the United States and South
America.
With more than 40 first patent applications per year, Symrise is one
of the most innovative manufacturers on the market. Used by
manufacturers of perfumes, cosmetics and foods, our products are an
inseparable part of daily life. At Symrise we combine an awareness of
consumer trends with cutting-edge technologies, focusing on
innovative fashion and lifestyle products that have additional
practical value for the consumer. Symrise - always inspiring more.
www.symrise.com
Contact: Katja Derow, phone: +49 40 4696770-10, e-mail:
k.derow@redroses-pr.com
Therapeutic Peptides Inc.
The until now privately held and managed US biotechnology company
Therapeutic Peptides Inc. specializes in the development and
production of bioactive peptides, peptide derivatives and in a
technology for their transdermal delivery.
The founder of TPI - Dr. Donald Owen - has been engaged in academic
and clinical research for over 30 years. He has served as
co-investigator on various research programs, among other places at
the Medical University of South Carolina and the University of
Southern Mississippi.
www.tpipeptides.com
--- End of Message ---
Symrise AG
Mühlenfeldstraße 1 Holzminden Germany
WKN: SYM999; ISIN:
DE000SYM9999; Index: MDAX, TecDAX;
Listed: Amtlicher Markt in Frankfurter Wertpapierbörse, Freiverkehr
in Bayerische Börse München,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Börse Berlin,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Prime Standard in Frankfurter Wertpapierbörse;
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.